CG Oncology Begins IPO Effort For Bladder Cancer Drug - Seeking …

Jan 5, 2024 · CG Oncology, Inc. has filed for a $100 million IPO to fund the development of its bladder cancer treatment. The company's lead candidate has shown promising results in …

CouponFollow Extension

$100
OFF

CG Oncology Begins IPO Effort For Bladder Cancer Drug - Seeking …

4 weeks from now

Jan 5, 2024 · CG Oncology, Inc. has filed for a $100 million IPO to fund the development of its bladder cancer treatment. The company's lead candidate has shown promising results in …

seekingalpha.com

$100
OFF

Bladder Cancer Biotech CG Oncology Files For A $100 Million IPO

4 weeks from now

Jan 2, 2024 · If successful, CG Oncology believes that this trial could serve as the basis for a Biologics License Application submission to the FDA. The Irvine, CA-based company was …

renaissancecapital.com

$380
OFF

Bladder Cancer Therapies Developer Raises $380M In The First …

4 weeks from now

Jan 25, 2024 · CG Oncology, a company that turns viruses into cancer therapies, has raised $380 million to fund clinical development of a therapy that the company believes could become a …

medcitynews.com

$105
OFF

CG Raises $105M Crossover Round To Fund Phase 3 Cancer Trial

4 weeks from now

Aug 2, 2023 · CG Oncology has raised the rarely seen crossover round. Once ubiquitous, the pre-IPO rounds have dried up in the biotech bear market—but CG’s fully enrolled phase 3 bladder …

fiercebiotech.com

$1
OFF

CG Oncology Targets Near $1 Bln Valuation In US IPO | Reuters

4 weeks from now

Jan 18 (Reuters) - Cancer drug developer CG Oncology said on Thursday it was targeting a valuation of nearly $1 billion for its initial public offering. The company is developing a therapy …

reuters.com

$100
OFF

CG Oncology, Inc. (CGON) Stock Price, Quote & News - Stock …

4 weeks from now

5 days ago · Bladder cancer biotech CG Oncology files for a $100 million IPO. CG Oncology, a Phase 3 biotech developing an oncolytic immunotherapy for bladder cancer, filed on Tuesday …

stockanalysis.com

FAQs about CG Oncology Begins IPO Effort For Bladder Cancer Drug - Seeking … Coupon?

Will CG Oncology IPO a $100 million IPO?

CG Oncology, Inc. has filed for a $100 million IPO to fund the development of its bladder cancer treatment. The company's lead candidate has shown promising results in Phase 3 trials, with a high rate of complete response. ...

Is apple cider good for bladder cancer?

Despite having many health benefits, there is not enough scientific evidence to say that apple cider is good for bladder cancer. ...

How big is CG oncology's market for bladder cancer treatment?

The global market for bladder cancer treatment is expected to reach $4.71 billion by 2026, driving potential growth for CG Oncology. I'll provide an update when we learn more IPO details from CG Oncology, Inc. management. Looking for more investing ideas like this one? Get them exclusively at IPO Edge. Learn More » ...

Is CG oncology a potential therapeutic for bladder-cancer patients?

The Irvine, Calif.-based biopharmaceutical company is developing a potential therapeutic for bladder-cancer patients who are unresponsive to immunotherapy Bacillus Calmette-Guerin treatment. CG Oncology did not say how many shares it planned to offer or give an estimated price range. ...

Will CG oncology be the first biotech IPO?

CG is now in the running to be among the first biotech IPOs of the new year, against a backdrop of mixed predictions on whether public listings will recover from their two-year slump. Five months after reeling in $105 million from a pre-IPO crossover round, CG Oncology is now ready to take the plunge and go public. ...

When will CG oncology start a bladder cancer study?

The company said in the filing that it expects to begin this study in the second half of 2024. CG Oncology’s main asset is cretostimogene, an oncolytic virus in late-stage development as a treatment for advanced bladder cancer. The IPO filing follows the report of interim efficacy data showing a 75% complete response rate. ...